Nuvectis Pharma (NVCT) Assets Average (2022 - 2026)

Nuvectis Pharma (NVCT) has 5 years of Assets Average data on file, last reported at $28.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 17.13% year-over-year to $28.6 million; the trailing twelve-month figure through Mar 2026 stood at $28.6 million (up 17.13% YoY), and the FY2025 full-year result was $25.2 million, up 33.14% from the prior year.
• Assets Average declined to $28.6 million in Q1 2026, from $33.6 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $33.6 million in Q4 2025 to a low of $12.1 million in Q1 2022.
• A 5-year average of $22.0 million and a median of $20.6 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average dropped 24.57% in 2024 and jumped 87.38% in 2025, its largest moves.
• Tracing NVCT's Assets Average over 5 years: stood at $22.6 million in 2022, then decreased by 8.45% to $20.7 million in 2023, then decreased by 13.35% to $18.0 million in 2024, then jumped by 87.38% to $33.6 million in 2025, then dropped by 15.14% to $28.6 million in 2026.
• Business Quant data shows NVCT's Assets Average at $28.6 million in Q1 2026, $33.6 million in Q4 2025, and $31.3 million in Q3 2025.